Format

Send to

Choose Destination
Drug Discov Today. 2013 Oct;18(19-20):1014-24. doi: 10.1016/j.drudis.2012.10.011. Epub 2012 Nov 3.

Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.

Author information

1
Chemistry Innovation Centre/Discovery Sciences, AstraZeneca R&D Mölndal, SE-43183 Mölndal, Sweden. Electronic address: Thierry.Kogej@astrazeneca.com.

Abstract

In this study, the screening collections of two major pharmaceutical companies (AstraZeneca and Bayer Pharma AG) have been compared using a 2D molecular fingerprint by a nearest neighborhood approach. Results revealed a low overlap between both collections in terms of compound identity and similarity. This emphasizes the value of screening multiple compound collections to expand the chemical space that can be accessed by high-throughput screening (HTS).

PMID:
23127858
DOI:
10.1016/j.drudis.2012.10.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center